Boehringer Ingelheim acquires Swiss biotech in bid to combat equine allergies

Boehringer Ingelheim that it has acquired Evax AG, a Swiss biotech company focused on equine health. Founded more than a decade ago at the University of Zurich, Evax has been exploring the use of therapeutic vaccines to address significant unmet needs in horses, particularly for the treatment of all...